Protalix BioTherapeutics (DE) (PLX) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Protalix BioTherapeutics (DE) (PLX) has outperformed Entrada Therapeutics (TRDA) over the past year, gaining 8.4% versus a loss of 4.1%. Entrada Therapeutics is the larger company by market cap ($218.4 million vs $218.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PLX | TRDA |
|---|---|---|
| Share price | $2.71 | $5.61 |
| Market cap | $218.35M | $218.43M |
| 1-day change | -0.73% | +3.51% |
| YTD return | +50.56% | -45.43% |
| 1-year return | +8.40% | -4.10% |
| 5-year return | +120.33% | — |
| P/E ratio (TTM) | 11.78 | — |
| Forward P/E | 4.37 | — |
| EPS (TTM) | $0.23 | $-4.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.19 | $16.45 |
| 52-week low | $1.60 | $5.15 |
| Distance from 52-week high | -15.05% | -65.90% |
| Analyst consensus | none | none |
| Avg. price target upside | +305.90% | +238.68% |
| Average volume | 731.66K | 362.82K |
| Shares outstanding | 80.57M | 38.94M |
| Employees | 226 | 152 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLX has outperformed TRDA by 12.5 percentage points over the past year.
About Protalix BioTherapeutics (DE)
PLX stock →Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Healthcare · Biotechnology · 226 employees
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Healthcare · Biotechnology · 152 employees
PLX vs TRDA FAQ
Which is bigger, Protalix BioTherapeutics (DE) or Entrada Therapeutics?
Entrada Therapeutics (TRDA) is larger, with a market capitalization of $218.43M compared with $218.35M for Protalix BioTherapeutics (DE) (PLX).
Which stock has performed better over the past year, PLX or TRDA?
PLX returned +8.40% over the past 12 months, compared with -4.10% for TRDA (price return, excluding dividends). Past performance does not predict future results.
Are Protalix BioTherapeutics (DE) and Entrada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.